Initiative Seeks to Educate Consumers about
Monoclonal Antibody Treatments
Labcorp (NYSE: LH), a leading global life sciences company, is
working with the U.S. Department of Health and Human Services (HHS)
to raise awareness of potentially lifesaving monoclonal antibody
COVID-19 therapies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210511006196/en/
Photo courtesy of Labcorp
Patients who test positive using Labcorp’s COVID-19 PCR test
will receive information about monoclonal antibody therapeutics
with their result. Additionally, Labcorp’s COVID-19 site provides
information about treatments and vaccines, including monoclonal
antibody therapies, and answers a variety of questions related to
testing options. As of May 7, Labcorp has processed more than 41
million COVID-19 PCR tests.
“We serve as a trusted source of information and have dedicated
ourselves to helping combat COVID-19 through diagnostic testing and
the development of lifesaving treatments and therapies,” said Brian
Caveney, M.D., chief medical officer and president, Labcorp
Diagnostics. “In partnership with HHS, we are raising awareness of
monoclonal antibody treatments that can play an essential role in
improving outcomes for those at high risk of severe COVID-19. If a
patient receives a positive COVID-19 test result, we encourage
doctors and patients to learn more about monoclonal antibody
treatments using the helpful tools provided on the HHS
website.”
Monoclonal antibody treatments are laboratory-made proteins that
mimic the immune system’s ability to fight off harmful pathogens
such as the virus that causes COVID-19. Two such treatments
currently have emergency use authorization (EUA) from the U.S. Food
and Drug Administration (FDA).
People who are at high risk for progressing to severe COVID-19
or hospitalization can potentially reduce their risk of becoming
very ill by receiving a monoclonal antibody treatment within the
first 10 days of illness. Early evidence suggests that monoclonal
antibody treatments can reduce the amount of SARS-CoV-2, the virus
that causes COVID-19, in a person’s system, which decreases the
likelihood of severe symptoms and hospitalization. For more
information about COVID-19 monoclonal antibody therapies and who is
eligible for treatment, visit https://combatcovid.hhs.gov/.
“The U.S. Department of Health and Human Services is committed
to ensuring that eligible patients who develop mild to moderate
cases of COVID-19 know that treatment is available,” said Meredith
Chuk, M.D., federal lead for the monoclonal antibody program. “This
treatment is readily available and can decrease the likelihood that
high-risk patients who test positive for the virus will develop
severe disease or require hospitalization. We welcome our new
partner Labcorp in educating patients about this treatment.”
To find a monoclonal antibody treatment location, visit the HHS
national map or contact the HHS call center toll-free at
1-877-332-6585.
Labcorp’s COVID-19 PCR test has not been FDA-cleared or
approved; it has been authorized by the FDA under an EUA only for
the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens. The test is authorized only for the duration
of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostic tests for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is
terminated or revoked sooner.
About Labcorp Labcorp is a leading global life sciences
company that provides vital information to help doctors, hospitals,
pharmaceutical companies, researchers, and patients make clear and
confident decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
70,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020.
Learn about Covance by Labcorp at www.Covance.com, and Labcorp at
www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.
About HHS HHS works to enhance and protect the health and
well-being of all Americans, providing for effective health and
human services and fostering advances in medicine, public health,
and social services. For more information about HHS, visit
www.hhs.gov or follow us on Twitter @hhsgov or Facebook @HHS.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including
but not limited to statements with respect to clinical laboratory
testing, the potential benefits of COVID-19 testing and our
responses to and the expected future impacts of the COVID-19
pandemic, collaborations with third parties and the expected impact
of such collaborations, and the opportunities for future
growth.
Each of the forward-looking statements is subject to change
based on various important factors, many of which are beyond the
company’s control, including without limitation, the impact of the
COVID-19 pandemic and its impact on our business and financial
condition and on general economic, business, and market conditions,
our ability (or inability) to execute on our plans to respond to
the COVID-19 pandemic, competitive actions and other unforeseen
changes and general uncertainties in the marketplace, changes in
government regulations, including healthcare reform, customer
purchasing decisions, including changes in payer regulations or
policies, other adverse actions of governmental and third-party
payers, changes in testing guidelines or recommendations, federal,
state, and local government responses to the COVID-19 pandemic, the
effect of public opinion on the company’s reputation, adverse
results in material litigation matters, the impact of changes in
tax laws and regulations, failure to maintain or develop customer
relationships, our ability to develop or acquire new products and
adapt to technological changes, failure in information technology,
systems or data security, adverse weather conditions, the number of
revenue days in a financial period, employee relations, personnel
costs, and the effect of exchange rate fluctuations. These factors,
in some cases, have affected and in the future (together with other
factors) could affect the company’s ability to implement the
company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
The company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Further information on
potential factors, risks and uncertainties that could affect
operating and financial results is included in the company’s most
recent Annual Report on Form 10-K and subsequent Forms 10-Q,
including in each case under the heading RISK FACTORS, and in the
company’s other filings with the SEC. The information in this press
release should be read in conjunction with a review of the
company’s filings with the SEC including the information in the
company’s most recent Annual Report on Form 10-K, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511006196/en/
Labcorp Contacts:
Media: Chris Allman-Bradshaw —
336-436-8263 Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024